Overview

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Status:
Recruiting
Trial end date:
2022-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of CKD-351
Phase:
Phase 2
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
Latanoprost